Affordable Access

deepdyve-link
Publisher Website

Distribution of prostate cancer recurrences on gallium‐68 prostate‐specific membrane antigen ( 68Ga‐PSMA) positron‐emission/computed tomography after radical prostatectomy with pathological node‐positive extended lymph node dissection

Authors
  • Huits, Thijs H.1
  • Luiting, Henk B.2
  • van der Poel, Henk G.1
  • Nandurkar, Rohan3
  • Donswijk, Maarten1
  • Schaake, Eva4
  • Vogel, Wouter1, 4
  • Roobol, Monique J.2
  • Wit, Esther1
  • Stricker, Phillip5, 6
  • Emmett, Louise3, 6
  • van Leeuwen, Pim J.1
  • 1 Netherlands Cancer Institute, The Netherlands , (Netherlands)
  • 2 Erasmus Medical Centre, The Netherlands , (Netherlands)
  • 3 St Vincent's Hospital Nuclear Medicine and PET Department, Australia , (Australia)
  • 4 The Netherlands Cancer Institute, The Netherlands , (Netherlands)
  • 5 St. Vincent's Prostate Cancer Centre, Australia , (Australia)
  • 6 Garvan Institute of Medical Research, Australia , (Australia)
Type
Published Article
Journal
British Journal of Urology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Apr 23, 2020
Volume
125
Issue
6
Pages
876–883
Identifiers
DOI: 10.1111/bju.15052
PMID: 32181951
PMCID: PMC7317723
Source
PubMed Central
Keywords
License
Unknown
External links

Abstract

Objectives To examine the anatomical distribution of prostate cancer (PCa) recurrence on gallium‐68 prostate‐specific membrane antigen (68Ga‐PSMA) positron‐emission tomography (PET)/computed tomography (CT) in patients with biochemical recurrence (BCR) after undergoing radical prostatectomy (RP) with pathological lymph node metastasis (pN1) in their extended pelvic lymph node dissection (ePLND), and to compare the location of PCa recurrence with the location of the initial lymph node metastasis at ePLND. Materials and Methods We retrospectively reviewed 100 patients with BCR (PSA 0.05–5.00 ng/mL) after RP with pN1 ePLND who underwent 68Ga‐PSMA PET/CT to guide salvage therapy. Clinical and pathological features and anatomical locations of PCa recurrence on 68Ga‐PSMA PET/CT were obtained, and management impact was recorded. Results In all, 68 patients (68%) had a positive and 32 patients (32%) had a negative 68Ga‐PSMA PET/CT result. Of the 68 patients with a positive 68Ga‐PSMA PET/CT, 44 (65%) showed abnormal uptake only in the pelvic area, seven (10%) only outside the pelvic area, and 17 (25%) both within and outside the pelvic area. 68Ga‐PSMA PET/CT‐positive pelvic lymph nodes were often (84%) detected on the same side as the lymph node metastasis diagnosed at ePLND. Based on the outcomes of the 68Ga‐PSMA PET/CT, change of management was noted in 68% of the patients. Conclusion Recurrence of PCa on 68Ga‐PSMA PET/CT was limited to the pelvis in the majority of patients with BCR after RP with pN1 ePLND. Moreover, recurrence was often detected on the same side as the lymph node metastasis at ePLND. The results confirm the diagnostic value of 68Ga‐PSMA PET/CT in patients with BCR after RP with pN1 ePLND. Prospective studies are needed to support the long‐term benefit of 68Ga‐PSMA PET/CT‐dictated management changes.

Report this publication

Statistics

Seen <100 times